BefejeződöttFázis nélkül
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial
A legfontosabb adatok
- Ki végzi
- Arthrex, Inc.
- Hol
- Danville, Knoxville és Winston-Salem (Egyesült Államok)Mind a 3 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 45 fő vett részt
- Kezdés
- 2024. máj. 13.
- Befejezés
- 2026. febr. 9.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- ACP Max™
- Depo-Medrol®
- A regiszteradat frissítve
- 2026. február 18.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Subject voluntarily decides to participate and signs the consent form
- Subject is ≥ 18 to 75 years of age
- Subject presents with symptomatic knee OA despite at least 6 months of one of the following conservative treatments; oral medications, analgesics, and/or anti-inflammatory medications
- Subject has documented radiographic evidence of OA in the tibiofemoral or patellofemoral compartment of the target knee (Kellgren-Lawrence Grades II-III), using radiographs performed within 12 weeks of screening
- Subject has a WOMAC pain score (WOMAC A) of at least 8 out of 20 and at least moderate degree of difficulty (a score of 2) for at least 2 questions on performing daily activities
- Subject consents to a washout period of NSAIDs and analgesics 7 days before each study visit (except low-dose aspirin for prevention of cardiovascular disease)
- Subject has a Body Mass Index ≤ 35 kg/m2
Ki nem vehet részt
- Subject has received an IA injection of corticosteroids in the target knee within 4 months prior to screening
- Subject did not achieve initial pain relief from prior corticosteroid injections
- Subject has received an IA injection of HA in the target knee within 6 months prior to screening
- Subject has received an IA injection of PRP in the target knee at any time prior to screening
- Subject had prior open surgery on the target knee within 12 months or knee arthroscopy within 6 months
- Subject plans to participate in other clinical trials involving medical or surgical intervention in the next 12 months
- Subject with plans to undergo any elective orthopedic surgery in the next 12 months
- Subject requires pain management therapy not related to the target knee (with the exception of acetaminophen)
- Subject has clinically 3+ effusion of the target knee (stroke test grading system)
- Subject has a history of coagulopathy
- Subject has an inflammatory disease of either knee other than OA
- Subject which, in the investigator's opinion, has an underlying medical condition(s) that could interfere with the evaluation of the outcome
- Subject with any condition (including cognitive impairment) that, in the investigator's opinion, might interfere with the evaluation of the study objectives
- Subject has an infection at the affected joint
- Subject has a history of major trauma to the target knee within one year
- Subject has a known hypersensitivity to Depo-Medrol and its constituents
- Subject has Grade I or IV in the target knee according to the Kellgren-Lawrence grading scale
- Subject has significant (> 10°) valgus or varus deformities as evidenced by standard of care x-ray
- Subject has joint pain reflected by a VAS score of > 35 mm out of 100 mm scale in the contralateral knee at the time of screening
- Subject with a positive pregnancy test or breastfeeding
- Subject has rheumatoid arthritis or gout
Helyszínek itt: Egyesült Államok
- Spectrum Medical, Inc.Danville, Egyesült Államok
- AMR KnoxvilleKnoxville, Egyesült Államok
- The Center for Clinical ResearchWinston-Salem, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).
A vizsgálat 2 csoportja
- ACP Max™A vizsgált kezelés
Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
- 40 mg of methylprednisolone acetateMár használt kezelés, összehasonlításként
Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
Kezelés: Depo-Medrol®
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. február 18.